Company intelligence / Profile preview
ENA Respiratory
Melbourne, Victoria, Australiaenarespiratory.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
INNA-051 has demonstrated accelerated virus clearance and stimulation of antiviral host defenses in a Phase IIa proof-of-principle study using a human influenza-challenge model. A Phase 1 study in older adults (66-80 years) showed INNA-051 was well-tolerated and increased important antiviral host-defense pathways. Pre-clinical data demonstrated reduced influenza virus dissemination to the lungs of aged mice.[5][7]
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small moleculesintranasal dry powder
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
COPD FoundationU.S. Department of DefenseFlu LabBLUE KNIGHT™ (Johnson & Johnson Innovation and BARDA initiative)[6][7][8]
Beyond the preview
Go deeper on ENA Respiratory.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ENA Respiratory.